The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
GEFCAPI 04: A phase III trial comparing a treatment oriented by a molecular analysis with CancerTYPE ID test to cisplatin-gemcitabine in patients with carcinoma of an unknown primary (CUP).
Geraldine Martineau
No relevant relationships to disclose
Agnes Laplanche
No relevant relationships to disclose
Agnes W Van de Wouw
No relevant relationships to disclose
Gedske Daugaard
No relevant relationships to disclose
Carmen Balana
No relevant relationships to disclose
Nicolas Penel
No relevant relationships to disclose
Loic Chaigneau
No relevant relationships to disclose
Djelila Allouache
No relevant relationships to disclose
Bruno Chauffert
No relevant relationships to disclose
Stephane Culine
No relevant relationships to disclose
Marine Gross-Goupil
No relevant relationships to disclose
Yacine Merrouche
No relevant relationships to disclose
Cristian Moldovan
No relevant relationships to disclose
Elodie Vauleon
No relevant relationships to disclose
Isabelle Borget
No relevant relationships to disclose
Fanny Wunder
No relevant relationships to disclose
Catherine A. Schnabel
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Karim Fizazi
No relevant relationships to disclose